Morgan Stanley Nanobiotix S.A. Transaction History
Morgan Stanley
- $1.36 Trillion
- Q1 2025
A detailed history of Morgan Stanley transactions in Nanobiotix S.A. stock. As of the latest transaction made, Morgan Stanley holds 6,100 shares of NBTX stock, worth $25,437. This represents 0.0% of its overall portfolio holdings.
Number of Shares
6,100
Previous 5,102
19.56%
Holding current value
$25,437
Previous $14,000
50.0%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding NBTX
# of Institutions
13Shares Held
6MCall Options Held
0Put Options Held
0-
Johnson & Johnson New Brunswick, NJ5.62MShares$23.5 Million6.69% of portfolio
-
Black Rock Inc. New York, NY239KShares$996,6630.0% of portfolio
-
Perceptive Advisors LLC New York, NY105KShares$438,0710.02% of portfolio
-
Jane Street Group, LLC New York, NY11.4KShares$47,4830.0% of portfolio
-
Geode Capital Management, LLC Boston, MA10.2KShares$42,4670.0% of portfolio
About Nanobiotix S.A.
- Ticker NBTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 34,875,900
- Market Cap $145M
- Description
- Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cance...